Rallybio to Present at Upcoming Investor Conferences in March

Rhea-AI Summary

Rallybio Corporation (Nasdaq: RLYB), a biotechnology company focused on therapies for rare diseases, will participate in two upcoming investor conferences. The Cowen 43rd Annual Healthcare Conference will take place on March 8, 2023 in Boston, featuring CEO Martin Mackay in a panel at 2:10 p.m. ET. Additionally, the Oppenheimer 33rd Annual Healthcare Conference is set for March 13, 2023, where COO Steve Uden will participate in a virtual fireside chat at 4:40 p.m. ET. Live webcasts of the presentations can be accessed on Rallybio’s website, with replays available for 30 days.

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences:

• Cowen 43^rd Annual Healthcare Conference in Boston, Massachusetts on Wednesday, March 8, 2023. Martin Mackay, Ph.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “Neuromuscular & Bone,” at 2:10 p.m. ET.

• Oppenheimer 33^rd Annual Healthcare Conference being held virtually on Monday, March 13, 2023. Steve Uden, M.D., President and Chief Operating Officer of Rallybio, will participate in a virtual fireside chat at 4:40 p.m. ET.

A live webcast of both presentations will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. A replay of the webcasts will be available for 30 days following each presentation.

About Rallybio

Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230224005394/en/

Investor

Ami Bavishi

Head of Investor Relations and Communications

475-47-RALLY (Ext. 282)

abavishi@rallybio.com

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Media

Tara DiMilia

908-369-7168

Tara.dimilia@tmstrat.com

Source: Rallybio Corporation

FAQ

What investor conferences is Rallybio Corporation participating in March 2023?

Rallybio Corporation is participating in the Cowen 43rd Annual Healthcare Conference on March 8, 2023, and the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023.

What time will Rallybio's CEO speak at the Cowen conference?

Rallybio's CEO, Martin Mackay, will participate in a panel discussion at 2:10 p.m. ET during the Cowen 43rd Annual Healthcare Conference.

When will the Oppenheimer Healthcare Conference take place?

The Oppenheimer 33rd Annual Healthcare Conference will take place on March 13, 2023.

Who is speaking at the Oppenheimer conference for Rallybio?

Steve Uden, M.D., President and COO of Rallybio, will participate in a virtual fireside chat at 4:40 p.m. ET during the Oppenheimer conference.

Where can I watch the webcasts of Rallybio's conference presentations?

The webcasts of Rallybio's presentations will be accessible through the Events and Presentations section of their website.